Citations 12
Skin Cancer Screening: Recommendations for Data-Driven Screening Guidelines and a review of the US Preventive Services Task Force Controversy
Johnson, Mariah, Aspinwall, Lisa G. , Cranmer, Lee D. , CurielâLewandrowski, Clara , Sondak, Vernon K. , Stemwedel, Clara E. , Vetto, John T. , Bowles, Tawnya L. , Grossmann, Kenneth F. , Jeter, Joanne, Kim, Caroline C. , Mangold, Aaron R. , Meyskens, Frank L. , Ming, Michael E. , Nelson, Kelly C. , Piepkorn, Michael W., Pollack, Brian P. , Sober, Arthur J., Trotter, Shannon C., Venna, Suraj , Agarwala, Sanjiv S. , Averbook, Bruce J., Bar, Anna, Becevic, Mirna , Cassidy, Pamela B. , Chu, Emily Y. , Ellis, Darrel L., Ferris, Laura K. , Fisher, David E. , Kendra, Kari , Lawson, David H. , Leming, Philip D. , Markovic, Svetomir, Martini, Mary C. , Miller, Debbie, Sahni, Debjani, Sharfman, William H. , Stein, Jennifer , Stratigos, Alexander , Wisco, Oliver J. , Wong, Michael K. , Leachman, Sancy A. , Swetter, Susan M. , Dellavalle, Robert Paul , Geskin, Larisa J. , Grossman, Douglas , Hawkes, Jason Ezra , Jeter, Joanne , Kirkwood, John M. , Robinson, June K. , Alani, Rhoda M. , Box, Neil F. , Carson, William E. , Chen, Suephy C. , Margolin, Kim , Markovic, Svetomir N. , Tarhini, Ahmad A. , Taylor, Matthew H. , Mangold, A R , Becevic, Mirna
Melanoma Management | March 1, 2017 | Volume: 4 | Issue: 1 | Pages: 13-37
BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma
Kim, Kevin B. , Sosman, Jeffrey A. , Fruehauf, John P. , Linette, Gerald P. , Nguyen, Hoa , Cheverton, Peter, Chen, Daniel S. , Peterson, Amy , Carson, William E. , Markovic, Svetomir N. , McDermott, David F. , Weber, Jeffrey S. , Peterson, Amy , O'Day, Steven J , Carson, William E
Journal of Clinical Oncology | November 29, 2011 | Volume: 30 | Issue: 1 | Pages: 34-41
Purpose Metastatic melanoma, a highly vascularized tumor with strong expression of vascular endothelial growth factor, has an overall poor prognosis. We conducted a placebo-controlled, double-blind phase II study of carboplatin plus paclitaxel with or without bevacizumab in patients with previously untreated metastatic melanoma. Patients and Methods Patients were randomly assigned in a two-to-one ratio to carboplatin (area under the curve, 5) plus paclitaxel (175 mg/m 2 ) and bevacizumab (15 mg/kg; CPB) or placebo (CP) administered intravenously once every 3 weeks. Progression-free survival (PFS) was the primary end point. Secondary end points included overall survival (OS) and safety. Results Two hundred fourteen patients (73% with M1c disease) were randomly assigned. With a median follow-up of 13 months, median PFS was 4.2 months for the CP arm (n = 71) and 5.6 months for the CPB arm (n = 143; hazard ratio [HR], 0.78; P = .1414). Overall response rates were 16.4% and 25.5%, respectively (P = .1577). With 13-month follow-up, median OS was 8.6 months in the CP arm versus 12.3 months in the CPB arm (HR, 0.67; P = .0366), whereas in an evaluation 4 months later, it was 9.2 versus 12.3 months, respectively (HR, 0.79; P = .1916). In patients with elevated serum lactate dehydrogenase (n = 84), median PFS and OS were longer in the CPB arm (PFS: 4.4 v 2.7 months; HR, 0.62; OS: 8.5 v 7.5 months; HR, 0.52). No new safety signals were observed. Conclusion The study did not meet the primary objective of statistically significant improvement in PFS with the addition of bevacizumab to carboplatin plus paclitaxel. A larger phase III study will be necessary to determine whether there is benefit to the addition of bevacizumab to carboplatin plus paclitaxel in this disease setting.